The biopharmaceutical market in Southeast Asia was valued at US$ 18.4 billion in 2023 and is projected to grow to US$ 37.6 billion by 2032, reflecting a compound annual growth rate (CAGR) of 8.25% from 2024 to 2032, driven by increasing healthcare investments, rising demand for innovative therapies, and growing prevalence of chronic diseases. https://www.imarcgroup.com/south-east-asia-biopharmaceutical-market